Sumary of ‘No new safety concerns’ emerge for ocrelizumab in MS subpopulations:
- September 10, 2021 2 min read Source/Disclosures Disclosures: Hauser reports serving on the board of trustees for Neurona and on scientific advisory boards for Alector, Annexon, Bionure and Molecular Stethoscope, as well as having received travel reimbursement and writing assistance from F.
- Please see the study for all other authors’ relevant financial disclosures.
- Back to Healio Continuous administration of ocrelizumab in clinical trials and its broader use in real-world settings exhibited a favorable and manageable safety profile for relapsing MS and primary progressive MS, according to a study in Neurology.
- Safety surveillance to understand the long-term benefit–risk profile of OCR in patients with MS (PwMS) is therefore warranted.
- ” In the current analysis, the investigators reported the safety profile of ocrelizumab for up to 7 years among patients with relapsing MS and primary progressive MS who participated in clinical trials or received treatment in real-world post-marketing settings.